Form 4: CG Oncology director sells 1,000 shares via 10b5-1

Director Leonard E. Post exercised 1,000 options at $0.6 and sold 1,000 shares at $41.43 on November 17, 2025 under a pre-set Rule 10b5-1 plan.

Summary

• Director Leonard E. Post executed an option exercise for 1,000 shares at $0.6 per share on 11/17/2025 and sold the 1,000 resulting common shares at $41.43 the same day.
• Transactions were conducted under a Rule 10b5-1 trading plan adopted on 09/06/2024.
• Post’s direct common stock holdings after the reported transactions: 0 shares.
• Remaining derivative securities (stock options) beneficially owned after the transactions: 117,077.
• Exercised options were fully vested; the option grant carries an expiration date of 07/08/2028.
• Form was signed by Attorney-in-Fact on 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral overall: a small, pre-planned insider exercise-and-sale with no operational or financial implications; continued significant option holdings mitigate negative interpretation.

Positives

• Sales executed under a Rule 10b5-1 plan adopted on 09/06/2024, indicating pre-planned trading rather than discretionary timing.
• Options exercised were fully vested, reducing concerns about accelerated vesting or unusual grants.
• Director retains a substantial option position (117,077 options) after the sale, maintaining economic exposure to the company.

Negatives

• Insider sold 1,000 shares at $41.43, resulting in 0 directly held common shares after the transactions.
• Exercise-and-sell pattern may be viewed negatively by some investors despite the pre-planned nature.

Future Outlook

No forward-looking statements or guidance are provided.

Management Comments

• Sales were effected pursuant to a Rule 10b5-1 trading plan adopted on September 6, 2024.
• Options exercised were fully vested.

Industry Context

Pre-planned Rule 10b5-1 insider transactions are common across biotech, especially among directors and executives managing concentrated equity exposure; the small size of this transaction and remaining option holdings suggest routine portfolio management rather than a signal about operations.

Comparison to Industry Standards

• Not applicable: this is a Form 4 insider transaction with no operational or financial results to benchmark; the pre-planned 10b5-1 sale and modest size align with standard governance practices.

Stakeholder Impact

• Shareholders may view the small, pre-planned sale as routine and not indicative of a change in company outlook.
• No changes to management roles or governance are indicated, implying no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

CG Oncology, CGON, Form 4, insider transaction, Rule 10b5-1, stock option exercise, insider sale, biotechnology, director trading, beneficial ownership